Structure of the final PK/PD model.

Slides:

Advertisements

Similar presentations

The half-life OCT 2010.

Advertisements

Pyry Välitalo Nonlinear mixed effects models in pharmacokinetic modeling Lecture notes.

Two-compartment model

Nieves Velez de Mendizabal 1, 2, Kimberley Jackson 3, Brian Eastwood 4, Steven Swanson 5, David M. Bender 5, Stephen Lowe 6, Robert R. Bies 1, 2 A Population.

The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.

Conclusions An appreciable dose-concentration-response relationship between NN1731 and F 1+2 was expressed in a population PK/PD model. Since F 1+2 appearance.

MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS

Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.

The General Concepts of Pharmacokinetics and Pharmacodynamics

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

COMPARTMENTAL ANALYSIS OF DRUG DISTRIBUTION

1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.

The General Concepts of Pharmacokinetics and Pharmacodynamics

1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.

Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.

From: Impact of P-Glycoprotein on Blood–Retinal Barrier Permeability: Comparison of Blood–Aqueous Humor and Blood–Brain Barrier Using Mdr1a Knockout Rats.

The 3-compartment pharmacokinetic model

Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.

Volume 111, Issue 10, Pages (November 2016)

Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic.

Uncertainty analyses with the mixing parameter and different distributions of the testing uptakes in the SB–RP groups (SB–RP model). Uncertainty analyses.

Dosimetry and Kinetics

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Volume 112, Issue 2, Pages (January 2017)

Volume 101, Issue 4, Pages (August 2011)

Appropriateness and total knee arthroplasty: an examination of the American Academy of Orthopaedic Surgeons appropriateness rating system D.L. Riddle,

Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia M Hara, K Masui, D.J. Eleveld,

Presynaptic inhibition of the release of multiple major central nervous system neurotransmitter types by the inhaled anaesthetic isoflurane R.I. Westphalen,

Volume 85, Issue 6, Pages (June 2014)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Ranjan K. Dash, Feng Qi, Daniel A. Beard Biophysical Journal

The two-compartment recirculatory pharmacokinetic model'an introduction to recirculatory pharmacokinetic concepts Upton R.N. British Journal of Anaesthesia

Colistin pharmacokinetics: the fog is lifting

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Hawler Medical University

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Pharmacokinetics of intranasal fentanyl in parturient

Observed (symbols) and model predicted (lines) dopamine time courses in rats following D-amphetamine administration. Observed (symbols) and model predicted.

MIC distributions of selected β-lactam antimicrobial agents for H

Drug Dosing Considerations in Alternative Hemodialysis

Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated.

Volume 111, Issue 10, Pages (November 2016)

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Covariates of tramadol disposition in the first months of life

Pharmacodynamic response modelling of arterial blood pressure in adult volunteers during propofol anaesthesia C. Jeleazcov, M. Lavielle, J. Schüttler,

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Are Astrocytes the Pressure-Reservoirs of Lactate in the Brain?

Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under.

Ranjan K. Dash, Feng Qi, Daniel A. Beard Biophysical Journal

Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.

Effect of 11-day oral administration of vehicle (n = 4) or 6-day oral administration of enalapril 10 mg/kg per day (n = 19), followed by 5-day oral administration.

Jeffrey R. Groff, Gregory D. Smith Biophysical Journal

Dan-dan Tian1, 2 et al. Acta Pharmacol Sin 2015; 36: 627–643;

unbound concentration µM

(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.

Observed (symbols) and predicted (solid lines, eq

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

D Frasca, C Dahyot-Fizelier, W Couet, B Debaene, O Mimoz, S Marchand

(Left) Observed (symbols) and model-predicted (lines) response (tail flick) vs. time of drug X after different doses given by the intravenous (red) and.

(Top) Observed (symbols) and model-predicted (lines) response-time data for latanoprost at the 0.1, 1.0, and 10 µg dose levels in the cat eye. (Top) Observed.

Fig. 4 Experimental design for algesimetry.

Fig. 2 Results of the learning and testing phases.

Fig. 6 Global sensitivity analysis illustrates the key model parameters that determine the sickling of RBCs. Global sensitivity analysis illustrates the.

S. Rüdiger, Ch. Nagaiah, G. Warnecke, J.W. Shuai Biophysical Journal

Fig. 3 Transition of adiabatic driving from the standard continuous protocol to the jumping protocol. Transition of adiabatic driving from the standard.

Fig. 3 Measured thermoelectric characteristics.

Fig. 3 Spatial distribution of the shoot density (high densities are represented in dark green and low ones in bright yellow) in a simulation of a P. oceanica.

Presentation transcript:

Structure of the final PK/PD model. Structure of the final PK/PD model. A two-compartment model for systemic disposition (“Peripheral d-amphetamine” compartment) applies only to the rat. Pharmacokinetic parameter definitions: Clcsf, clearance from ECF to CSF; Clin, uptake clearance from plasma to brain ECF; Clout, efflux clearance from brain ECF to plasma; Clp, clearance from the central compartment; Q, intercompartmental distribution clearance; Qcsf-plasma, distributional clearance between plasma and CSF; Vb, unbound volume of distribution in the brain; Vc, volume of central compartment; Vcsf, volume of the CSF compartment; Vp, volume of the peripheral compartment. Pharmacodynamic parameter definitions: kin, zero-order rate constant for dopamine release into the synapse; kout, first-order rate constant for dopamine reuptake into the presynaptic nerve terminal; ktol, first-order rate constant for production and dissipation of the moderator response. Buffering of the moderator response owing to dose-dependent increases in the duration and extent of the dopamine effect is indicated by the dashed outlined box, and corresponds to eq. 8a in the text. Circled numbers in the figure correspond to those used in Fig. 1. Marcel M. van Gaalen et al. J Pharmacol Exp Ther 2019;369:107-120 Copyright © 2019 The Author(s).